Topical Minoxidil Therapy for Hereditary Male Pattern Alopecia

This article reviews the cellular dynamics affecting dermal papilla size in androgenetic alopecia and suggests targeting DP size could improve therapies, but it presents no new clinical data.

This article discusses the nature and causes of hair loss, including hereditary factors, but reports no new clinical findings.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This review discusses various types of hair loss, including androgenetic alopecia, telogen effluvium, and alopecia areata, and reports no new experimental findings.

This open-pilot study found that topical 1% sildenafil did not show significant hair growth in children with alopecia areata, as outcomes seemed due to spontaneous disease regression.

This study found that using a topical 2% minoxidil solution for 6-12 months may reduce hair loss and improve hair root conditions in some women with androgenic alopecia.

In an open trial, 2.8% minoxidil solution applied topically stimulated new hair growth in 45% of male patients with male pattern alopecia, though patient self-assessments were more favorable than objective evaluations.